Evaluating practitioner-blinding in Chinese herbal medicine research: Findings from a randomised feasibility study in the United Kingdom
Lily Yuen Wan Lai, Andrew Flower, Philip Prescott, Michael Moore, George T. Lewith
Abstract
Open-access reader
Lily Yuen Wan Lai, Andrew Flower, Philip Prescott, Michael Moore, George T. Lewith
Abstract
Open-access reader
Purpose: Practitioner-blinding is often carried out in randomised controlled trials (RCTs) of Chinese herbal medicines (CHMs) yet evaluation of blinding is infrequently conducted.We aimed to evaluate the feasibility of practitioner-blinding within a UK study and identify reasons for practitioner guesses.Methods: We conducted a practitioner and patient-blind feasibility study exploring CHM for polycystic ovary syndrome, randomising 40 women to standardised CHM or individualised CHM for 24 weeks.We evaluated practitioner-blinding at Week 4, 12 and End of Study (EoS).This questionnaire invited a treatment allocation guess (Standardised/Individualised) and certainty rating (Not at all sure, just guessed/Fairly sure/Entirely sure).This was used to calculate a Bang Blinding Index (BBI).The final item asked for reasons for their answer, analysed using content analysis.Results: Completion rates of blinding-questionnaire was excellent (mean=86%).Practitioner-guessing and BBI at Week 4 was standardised random/individualised unblinded (standardised -0.11,95%CI -0.35 to 0.14; individualised 0.47,95%CI 0.2 3 to 0.71), at Week 12 standardised random/individualised unblinded (standardised -0.24,95%CI -0.54 to 0.07; individualised 0.50,95%CI 0.12 to 0.88); EoS standardised opposite/individualised unblinded (standardised -0.56,95%CI -0.9 1 to -0.20; individualised 0.61,95%CI 0.30 to 0.92).'Presence of effects' was the highest ranking reason for treatment guess (52% of responses) and consistently led to a guess of 'individualised treatment'/'not at all sure', and 'absence of effect' consistently led to a guess of 'standardised treatment'/'not at all sure'.This can be interpreted as 'wishful thinking' scenario whereby the practitioner consistently believed treatment response was due to individualised treatment, suggesting that blinding was likely secure. Conclusion:We have demonstrated that practitionerblinding is feasible and likely secure in this feasibility study.To our knowledge, this is the first time practitioner-blinding has been rigorously evaluated in a CHM study in the UK.Qualitative data has provided further insight into practitioner reasons for treatment guess which will be used to maximise practitioner-blinding in future studies.
OpenAlex reports 2 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Purpose: Practitioner-blinding is often carried out in randomised controlled trials (RCTs) of Chinese herbal medicines (CHMs) yet evaluation of blinding is infrequently conducted.We aimed to evaluate the feasibility of practitioner-blinding within a UK study and identify reasons for practitioner guesses.Methods: We conducted a practitioner and patient-blind feasibility study exploring CHM for polycystic ovary syndrome, randomising 40 women to standardised CHM or individualised CHM for 24 weeks.We evaluated practitioner-blinding at Week 4, 12 and End of Study (EoS).This questionnaire invited a treatment allocation guess (Standardised/Individualised) and certainty rating (Not at all sure, just guessed/Fairly sure/Entirely sure).This was used to calculate a Bang Blinding Index (BBI).The final item asked for reasons for their answer, analysed using content analysis.Results: Completion rates of blinding-questionnaire was excellent (mean=86%).Practitioner-guessing and BBI at Week 4 was standardised random/individualised unblinded (standardised -0.11,95%CI -0.35 to 0.14; individualised 0.47,95%CI 0.2 3 to 0.71), at Week 12 standardised random/individualised unblinded (standardised -0.24,95%CI -0.54 to 0.07; individualised 0.50,95%CI 0.12 to 0.88); EoS standardised opposite/individualised unblinded (standardised -0.56,95%CI -0.9 1 to -0.20; individualised 0.61,95%CI 0.30 to 0.92).'Presence of effects' was the highest ranking reason for treatment guess (52% of responses) and consistently led to a guess of 'individualised treatment'/'not at all sure', and 'absence of effect' consistently led to a guess of 'standardised treatment'/'not at all sure'.This can be interpreted as 'wishful thinking' scenario whereby the practitioner consistently believed treatment response was due to individualised treatment, suggesting that blinding was likely secure. Conclusion:We have demonstrated that practitionerblinding is feasible and likely secure in this feasibility study.To our knowledge, this is the first time practitioner-blinding has been rigorously evaluated in a CHM study in the UK.Qualitative data has provided further insight into practitioner reasons for treatment guess which will be used to maximise practitioner-blinding in future studies.
Key concepts: Blinding, Alternative medicine, Medicine, Traditional medicine, Family medicine, Randomized controlled trial, Internal medicine, Pathology